{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:57:51Z","timestamp":1771930671980,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T00:00:00Z","timestamp":1523491200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s12032-018-1125-4","type":"journal-article","created":{"date-parts":[[2018,4,12]],"date-time":"2018-04-12T02:08:51Z","timestamp":1523498931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The impact of chemotherapy and its timing on survival in malignant peritoneal mesothelioma treated with complete debulking"],"prefix":"10.1007","volume":"35","author":[{"given":"Samer A.","family":"Naffouje","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiara A.","family":"Tulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George I.","family":"Salti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,12]]},"reference":[{"issue":"3","key":"1125_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2486\/indhealth.45.379","volume":"45","author":"C Bianchi","year":"2007","unstructured":"Bianchi C, Bianchi T. Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health. 2007;45(3):379\u201387.","journal-title":"Ind Health"},{"issue":"15","key":"1125_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1056\/NEJMra050152","volume":"353","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353(15):1591\u2013603.","journal-title":"N Engl J Med"},{"issue":"6799","key":"1125_CR3","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/35023079","volume":"406","author":"CK Stover","year":"2000","unstructured":"Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, Hickey MJ, Brinkman FS, Hufnagle WO, Kowalik DJ, Lagrou M, Garber RL, Goltry L, Tolentino E, Westbrock-Wadman S, Yuan Y, Brody LL, Coulter SN, Folger KR, Kas A, Larbig K, Lim R, Smith K, Spencer D, Wong GK, Wu Z, Paulsen IT, Reizer J, Saier MH, Hancock RE, Lory S, Olson MV. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature. 2000;406(6799):959\u201364.","journal-title":"Nature"},{"issue":"6","key":"1125_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/CEJ.0b013e3282f0c0a2","volume":"17","author":"MJ Teta","year":"2008","unstructured":"Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED. US mesothelioma patterns 1973\u20132002: indicators of change and insights into background rates. Eur J Cancer Prev. 2008;17(6):525\u201334.","journal-title":"Eur J Cancer Prev"},{"issue":"6","key":"1125_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/annonc\/mdl345","volume":"18","author":"P Boffetta","year":"2007","unstructured":"Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol. 2007;18(6):985\u201390.","journal-title":"Ann Oncol"},{"issue":"1","key":"1125_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jso.21167","volume":"99","author":"D Rodriguez","year":"2009","unstructured":"Rodriguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: defining the role of surgery. J Surg Oncol. 2009;99(1):51\u20137.","journal-title":"J Surg Oncol"},{"issue":"1","key":"1125_CR7","first-page":"79","volume":"7","author":"HR Alexander Jr","year":"2016","unstructured":"Alexander HR Jr, Burke AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7(1):79\u201386.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"1125_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1245\/s10434-014-3978-x","volume":"22","author":"JH Helm","year":"2015","unstructured":"Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. 2015;22(5):1686\u201393.","journal-title":"Ann Surg Oncol"},{"issue":"24","key":"1125_CR9","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1125_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","volume":"21","author":"D Magge","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014;21(4):1159\u201365.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1125_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3816\/CLC.2005.n.020","volume":"7","author":"PA Janne","year":"2005","unstructured":"Janne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Taylor L, Ashland J, Ye Z, Monberg MJ, Obasaju CK. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005;7(1):40\u20136.","journal-title":"Clin Lung Cancer"},{"issue":"21","key":"1125_CR12","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","volume":"26","author":"GR Simon","year":"2008","unstructured":"Simon GR, Verschraegen CF, Janne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008;26(21):3567\u201372.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1125_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D, Liu Y, Blatter J, Visseren-Grul C, Stahel R. Malignant peritoneal mesothelioma\u2014results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer. 2009;64(2):211\u20138.","journal-title":"Lung Cancer"},{"issue":"4","key":"1125_CR14","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20(4):1093\u2013100.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1125_CR15","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1245\/s10434-014-3803-6","volume":"21","author":"JT Miura","year":"2014","unstructured":"Miura JT, Johnston FM, Gamblin TC, Turaga KK. Current trends in the management of malignant peritoneal mesothelioma. Ann Surg Oncol. 2014;21(12):3947\u201353.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1125_CR16","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/cncr.25640","volume":"117","author":"TD Yan","year":"2011","unstructured":"Yan TD, Deraco M, Elias D, Glehen O, Levine EA, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH, Peritoneal Surface Oncology G. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer. 2011;117(9):1855\u201363.","journal-title":"Cancer"},{"issue":"36","key":"1125_CR17","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, Gilly FN, Levine EA, Shen P, Mohamed F, Moran BJ, Morris DL, Chua TC, Piso P, Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237\u201342.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1125_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.ejso.2017.01.009","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol. 2017;43(7):1228\u201335.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"1125_CR19","doi-asserted-by":"publisher","first-page":"e105919","DOI":"10.1371\/journal.pone.0105919","volume":"9","author":"R Kanteti","year":"2014","unstructured":"Kanteti R, Dhanasingh I, Kawada I, Lennon FE, Arif Q, Bueno R, Hasina R, Husain AN, Vigneswaran W, Seiwert T, Kindler HL, Salgia R. MET and PI3\u00a0K\/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS ONE. 2014;9(9):e105919.","journal-title":"PLoS ONE"},{"issue":"11","key":"1125_CR20","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabro","year":"2013","unstructured":"Calabro L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104\u201311.","journal-title":"Lancet Oncol"},{"issue":"20","key":"1125_CR21","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2011.41.5869","volume":"30","author":"HL Kindler","year":"2012","unstructured":"Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Janne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine\/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012;30(20):2509\u201315.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1125_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.lungcan.2012.05.111","volume":"77","author":"JE Dowell","year":"2012","unstructured":"Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. Lung Cancer. 2012;77(3):567\u201371.","journal-title":"Lung Cancer"},{"issue":"2","key":"1125_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.25555","volume":"117","author":"S Varghese","year":"2011","unstructured":"Varghese S, Chen Z, Bartlett DL, Pingpank JF, Libutti SK, Steinberg SM, Wunderlich J, Alexander HR Jr. Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. Cancer. 2011;117(2):361\u201371.","journal-title":"Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1125-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T20:30:55Z","timestamp":1555014655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1125-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1125-4","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not have any personal, institutional, or financial affiliations to disclose. The authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"69"}}